hotspot
The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.
The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.
advertisement
But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
States should stop sabotaging methadone treatment reform
Next article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： The cancer drug shortage isn’t new — and neither are the solutions
